Spinal Cord Injury Investor Symposium: NervGen's CEO on how NVG-291 aims to block an inhibitor that may be preventing natural nervous system repair

blonca9
Jun 26, 2024
1 min read

Mike Kelly explains the scientific rational for this peptide-based treatment, highlights its preclinical and phase 1 profile, and describes a unique P1b/2a clinical study design going forward.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Spinal Cord Injury Investor Symposium: NervGen's CEO on how NVG-291 aims to block an inhibitor that may be preventing natural nervous system repair

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight